• Publications
  • Influence
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors.
IMPORTANCE Although growing evidence points to highly indolent behavior of encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC), most patients with EFVPTC are treated as havingExpand
  • 716
  • 100
  • Open Access
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
BACKGROUND Poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) are rare and frequently lethal tumors that so far have not been subjected to comprehensive geneticExpand
  • 345
  • 49
  • Open Access
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
BACKGROUND TERT encodes the reverse transcriptase component of telomerase, which adds telomere repeats to chromosome ends, thus enabling cell replication. Telomerase activity is required for cellExpand
  • 269
  • 27
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Patients with poorly differentiated thyroid cancers (PDTC), anaplastic thyroid cancers (ATC), and radioactive iodine-refractory (RAIR) differentiated thyroid cancers have a high mortality,Expand
  • 426
  • 24
  • Open Access
Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns
The follicular variant of papillary thyroid carcinoma usually presents as an encapsulated tumor and less commonly as a partially/non-encapsulated infiltrative neoplasm. The encapsulated form rarelyExpand
  • 261
  • 23
  • Open Access
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.
The RAF inhibitor vemurafenib (PLX4032) increases survival in patients with BRAF-mutant metastatic melanoma, but has limited efficacy in patients with colorectal cancers. Thyroid cancer cells areExpand
  • 257
  • 23
  • Open Access
Solitary fibrous tumors of the head and neck: a clinicopathologic and radiologic review.
OBJECTIVE To describe the clinicopathologic and radiologic features of solitary fibrous tumors of the head and neck. DESIGN Retrospective analysis. SETTING Tertiary referral center that performsExpand
  • 102
  • 17
  • Open Access
Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).
BACKGROUND The Bethesda System for Reporting Thyroid Cytopathology is the standard for interpreting fine needle aspiration (FNA) specimens. The "atypia of undetermined significance/follicular lesionExpand
  • 182
  • 16
  • Open Access
Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice
Mutations of BRAF are found in ∼45% of papillary thyroid cancers and are enriched in tumors with more aggressive properties. We developed mice with a thyroid-specific knock-in of oncogenic BrafExpand
  • 156
  • 14
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
BACKGROUND Metastatic thyroid cancers that are refractory to radioiodine (iodine-131) are associated with a poor prognosis. In mouse models of thyroid cancer, selective mitogen-activated proteinExpand
  • 451
  • 13